Article Text
Editorial
Considering IL-6
Statistics from Altmetric.com
Targeting interleukin (IL)−6 or its receptor for the treatment of inflammatory disease is an attractive approach to the management of complex inflammatory diseases, especially those with a systemic component to their presentation and comorbidity. Biological drugs that target IL-6 receptor are already in clinical practice. Recently, more agents are emerging from clinical trials that block distinct parts of the IL-6/IL-6R pathway.
In this edition, Jones et al explore the rich diversity of biology mediated by IL-6. …